Abstract:TLR-7/8 agonists are a well-known class of vaccine adjuvants, with a leading example now included in Covaxin, a licensed human COVID-19 vaccine. This thereby provides the opportunity to develop newer, more potent adjuvants based on structure-function studies of these classes of compounds. Imidazoquinoline-based TLR7/8 agonists are the most potent, but when used as a vaccine adjuvant side effects can arise due to diffusion from the injection site into a systemic circulation. In this work, we sought to address this issue through structural modifications in the agonists to enhance their adsorption capacity to the classic adjuvant alum. We selected a potent TLR7-selective agonist, BBIQ (EC50 = 0.85 μM), and synthesized polyphenolic derivatives to assess their TLR7 agonistic activity and adjuvant potential alone or in combination with alum. Most of the phenolic derivatives were more active than BBIQ and, except for 12b, all were TLR7 specific. Although the synthesized compounds were less active than resiquimod, the immunization data on combination with alum, specifically the IgG1, IgG2b and IgG2c responses, were superior in comparison to BBIQ as well as the reference standard resiquimod. Compound 12b was 5-fold more potent (EC50 = 0.15 μM in TLR7) than BBIQ and induced double the IgG response to SARS-CoV-2 and hepatitis antigens. Similarly, compound 12c (EC50 = 0.31 μM in TLR7) was about 3-fold more potent than BBIQ and doubled the IgG levels. Even though compound 12d exhibited low TLR7 activity (EC50 = 5.13 μM in TLR7), it demonstrated superior adjuvant results, which may be attributed to its enhanced alum adsorption capability as compared with BBIQ and resiquimod. Alum-adsorbed polyphenolic TLR7 agonists thereby represent promising combination adjuvants resulting in a balanced Th1/Th2 immune response.

Conjugation of Weak Ligands with Weak Antigens to Activate TLR-7: A Step Toward Better Vaccine Adjuvants.

Synthesis and Evaluation of Conjugates of Novel TLR7 Inert Ligands As Self-Adjuvanting Immunopotentiators.

Synthesis and Immunoregulatory Activities of Conjugates of a Toll-like Receptor 7 Inert Ligand

Toll-like receptor 7 inactive ligands enhanced cytokine induction by conjugation to weak antigens.

Conjugation of TLR7 and TLR7/8 agonists onto weak protein antigen via versatile oxime ligation for enhanced vaccine efficacy

Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators

Identification of novel and potent synthetic TLR agonists

Structure−Activity Relationships Towards the Identification of High-Potency Selective Human Toll-Like Receptor-7 Agonist

Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists

Design and Synthesis of Polyphenolic Imidazo[4,5- c]quinoline Derivatives to Modulate Toll Like Receptor-7 Agonistic Activity and Adjuvanticity

Synthesis and immunological evaluation of a low molecular weight saccharide with TLR-4 agonist activity

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases

Strategic Development of a Self-Adjuvanting SARS-CoV-2 RBD Vaccine: from Adjuvant Screening to Enhanced Immunogenicity with a Modified TLR7 Agonist

Toll-like Receptor Ligands Differentially Activate Human Innate Immune System and Distinctively Enhance Antigen-Specific T Cell Response to Vaccination in Humanized Mice (VAC4P.1105)

A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7

A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant

Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants

Codelivery of Nod2 and Tlr9 Ligands Via Nanoengineered Protein Antigen Particles for Improving and Tuning Immune Responses

Design, Synthesis and Immunological Evaluation of Monophosphoryl Lipid A Derivatives As Adjuvants for a RBD-hFc Based SARS-CoV-2 Vaccine

Study on the agonists for the human Toll-like receptor-8 by molecular modeling.

Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases